Riskpilot← Back to searchSign inGet full accessIMPLANTSCAN AS
ASActiveOrg 989898051Grini Næringspark 1, 1361 ØsteråsWholesale of pharmaceutical and medical goods · NACE 4646Est. 20065 employees
Revenue 2024
NOK 20,6M
+5% vs 2023
EBITDA margin
0.1%
-97% vs 2023
Equity ratio
12.1%
Financial strength
Net profit 2024
NOK -937K
-90% vs 2023
| Revenue | NOK 20,6M | +5% |
| EBITDA | NOK 24K | -97% |
| Net profit | NOK -937K | -90% |
| Total assets | NOK 10,6M | +15% |
| Equity | NOK 1,3M | -42% |
| Employees | 5 | — |
Legal name
IMPLANTSCAN AS
Org number
989898051
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
14. juni 2006
Share capital
NOK 100 000
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene. Daglig leder alene.
Company purpose
Import/salg av utstyr til helsetoren og andre produkter som naturlig faller sammen med dette, herunder å delta i andre selskaper med lignende virksomhet, kjøp og salg av aksjer, eller på annen måte gjøre seg interessert i andre foretagender.
Address
Grini Næringspark 1, 1361 Østerås
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 22 017 | 23 089 | 24 969 | 19 639 | 20 585 |
| Staff expenses | −5 759 | −5 703 | −4 680 | −5 767 | −6 016 |
| EBITDA | 1 844 | 215 | 1 162 | 764 | 24 |
| Depreciation & amort. | −232 | −736 | −802 | −733 | −806 |
| EBIT | 1 612 | −522 | 360 | 31 | −782 |
| Net financials | −69 | 108 | −253 | −524 | −155 |
| Profit before tax | 1 543 | −414 | 107 | −493 | −937 |
| Tax | 368 | −69 | 32 | −0 | −0 |
| Net profit | 1 176 | −345 | 75 | −493 | −937 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 11 546 | 8 959 | 10 200 | 9 182 | 10 599 |
| Equity | 3 482 | 3 137 | 3 212 | 2 219 | 1 282 |
| Long-term debt | 129 | 53 | 0 | 0 | 0 |
| Short-term debt | 7 935 | 5 769 | 6 988 | 6 963 | 9 317 |
| Total debt | 8 064 | 5 822 | 6 988 | 6 963 | 9 317 |
EBITDA margin
0.1%
This company
15.8%
Market median
-99% vs market
20202024
Equity ratio
12.1%
This company
38.2%
Market median
-68% vs market
20202024
Return on equity
-73.1%
This company
18.4%
Market median
-497% vs market
20202024
Net profit margin
-4.6%
This company
8.1%
Market median
-157% vs market
20202024
Asset turnover
1.94×
This company
1.12×
Market median
+73% vs market
20202024
Debt / equity
7.27×
This company
0.62×
Market median
-1073% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
PE Chief Executive Officer | Chief Executive Officer | 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2023 | |
| Board of Directors | 2023 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of IMPLANTSCAN AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Philip Edward Essebaggers | Chief Executive Officer | 0 companies |
| Geir Prestbakmo | Chairman | 0 companies |
| Åse Beate Pedersen | Board of Directors | 0 companies |